98%
921
2 minutes
20
"Assessing the quality by distinguishing features of traditional Chinese medicinal materials" is a characteristic quality evaluation system of traditional Chinese medicine, and it is also the basis of "Rating according to characters and setting the price by the grade" on the market. Astragali Radix was regarded as a famous traditional Chinese medicine (TCM), and this paper has carried out herbal textual research on the development and formation of the concept, "assessing the quality by distinguishing features of traditional Chinese medicinal materials", of Astragali Radix. The authentic medicine producing areas of Astragalus in China have experienced a great change, Gansu , Sichuan and adjacent areas before the Tang Dynasty; Shanxi during the Tang and Song Dynasty. The concept, "assessing the quality by distinguishing features of traditional Chinese medicinal materials", of Astragali Radix was formed in the Song and Ming Dynasty and still used today, which described as that the shape is "straight as an arrow"; the texture is "soft as cotton"; the section looks like" gold well and jade hurdle"; it was sweet in taste and has beany flavor. The system, "assessing the quality by distinguishing features of traditional Chinese medicinal materials", of Astragali Radix has undergone the adjustments from "true or false" to "good or bad", advance with the times, pick out the advantages from others and absorb the experience of traditional identification actively. Besides, it always returns to laconism from erudition and was summarized highly. Assessing the quality by distinguishing features of traditional Chinese medicinal materials and commodity specifications have the same root, so the former has reference meaning to revise the latter.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.19540/j.cnki.cjcmm.2017.0066 | DOI Listing |
J Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
Biomed Chromatogr
October 2025
Department of Rehabilitation, Nan'ao People's Hospital, Shenzhen, China.
Chrysotobibenzyl, a bioactive ingredient from Dendrobium chrysotoxum, exhibits potent anti-tumor activity. However, its metabolic profiles remain unelucidated. This study aimed to disclose the metabolic fates of chrysotobibenzyl using human liver fractions.
View Article and Find Full Text PDFBMC Psychiatry
September 2025
Department of Cardiovascular, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Jiangxi, Nanchang, 330006, China.
Int J Lab Hematol
September 2025
Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Background: T follicular helper (TFH) cell lymphoma is complex, and we hope to provide a new perspective for its diagnosis.
Methods: We analysed the immunophenotypes of 89 mature T-cell lymphomas, including 52 nodal lymphomas of TFH origin, as well as 32 benign lymph node samples and 30 healthy bone marrow samples, by flow cytometry (FCM).
Results: Among pan-T cell markers, CD4CD5CD3 is the typical pattern that distinguishes TFH lymphoma from other T-cell lymphomas.
Cytokine Growth Factor Rev
September 2025
Shandong University of Traditional Chinese Medicine, Jinan 250355, China; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, China. Electronic address:
This review summarizes the biological properties of key myokines (Irisin, Apelin, CLCF1, and Myostatin) and osteokines (Osteocalcin, Sclerostin, FGF23 and the RANKL/OPG system). This work provides an in-depth analysis of the age-related network imbalance mechanism characterized by "downregulation of protective factors (Irisin, CLCF1, and uncarboxylated Osteocalcin) - upregulation of pro-degenerative factors (Myostatin, Sclerostin, and FGF23) - inflammation-driven amplification", and reveals the mechanism by which this network imbalance contributes to the comorbidity of sarcopenia, osteoporosis, and neurodegenerative diseases. Furthermore, the review evaluates the intersecting regulatory networks and molecular pathways through which myo-osteogenic factors modulate neurotrophic factors (BDNF, NGF and GDNF), and proposes intervention strategies based on these intersecting regulatory networks.
View Article and Find Full Text PDF